Anti-Aging Facial Skin Tightening Device — FDA Cleared LED

The Lumara VISO Mask and Illuminate V2 Red Panel are both FDA Cleared Class II medical devices using clinical-grade 660nm red light wavelength. The VISO uses 470 MICRO-LEDs for full-face coverage, while the Illuminate V2 panel features 1,800+ LEDs covering 1,200 cm² for facial and full-body treatments — both triple-tested for wavelength precision.

The Lumara Illuminate Blue Panel emits 415nm blue light therapy. Simply position the panel 1–2 inches from the treatment area and run a 5-minute session. The 200-degree beam angle and 1,800 LEDs ensure uniform coverage across cheeks, temples, and jawline. Silicon goggles are included for eye protection. It is suitable for daily professional or home use.

For deep wrinkles, red (660nm) and near-infrared (830nm) wavelengths are most effective, as they penetrate deeper into the dermis to stimulate collagen and elastin production. The Lumara PRO 5-wavelength system delivers up to 120 mW/cm² across five wavelengths, while the VISO Mask and Illuminate V2 Panel deliver targeted 660nm therapy for visible anti-aging results within the first week.

Yes. All Lumara devices feature 40,000+ hour LED lifespans supporting daily professional or home use for over 19 years. They are FDA Cleared Class II medical devices, include eye protection accessories, and are designed with no infrared risk in the VISO Mask to prevent retinal damage or conditions such as melasma worsening.

Yes. The Illuminate panels (Blue, Green, and V2 Red) are designed for full-body applications including back, stomach, chest, shoulders, knees, feet, and hands. The Lumara PRO stand unit also supports full-body treatment across multiple wavelengths. The flexible, portable design makes both home and clinical multi-area treatments straightforward and efficient.

Yes. All Lumara Systems products — including the VISO Mask, Illuminate V2, Illuminate Blue, Illuminate Green, and Lumara PRO — are HSA and FSA eligible under qualifying health savings and flexible spending account guidelines. This makes clinical-grade LED therapy more financially accessible for both individual consumers and healthcare practice budgets.